---
layout: post
title: "Assessing User Fees Under the Generic Drug User Fee Amendments of 2017; Guidance for Industry; Availability"
date: 2026-02-05 18:59:11 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-10702
original_published: 2022-05-18 00:00:00 +0000
significance: 8.00
---

# Assessing User Fees Under the Generic Drug User Fee Amendments of 2017; Guidance for Industry; Availability

**Published:** February 05, 2026 18:59 UTC
**Source:** Federal Register
**Original Published:** May 18, 2022 00:00 UTC
**Document Number:** 2022-10702

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Assessing User Fees Under the Generic Drug User Fee Amendments of 2017." This guidance provides stakeholders information regarding the implementation of the Generic Drug User Fee Amendments of 2017 (GDUFA II) and policies and procedures surrounding its application. This guidance is finalizing FDA's draft guidance for industry "Assessing User Fees Under the Generic Drug User Fee Amendments of 2017," published in November 2019.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/05/18/2022-10702/assessing-user-fees-under-the-generic-drug-user-fee-amendments-of-2017-guidance-for-industry)
- API: https://www.federalregister.gov/api/v1/documents/2022-10702

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
